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Summary: The paracrine renal endothelin system has been implicated in acute and chronic kidney diseases. How-
ever, there are only few data about the expression of endothelin receptor subtypes and their impact on renal function
in the normal rat kidney. Therefore, we analyzed the age-dependent expression of endothelin receptors (endothelin
receptor A and B) using Scatchard analysis, in vitro and in vivo receptor autoradiography. Furthermore, we investi-
gated the effects of the mixed (A/B) endothelin receptor antagonist bosentan on haemodynamic and renal function
in conscious chronically instrumented rats. The renal endothelin receptor A and endothelin receptor B expression
is age-dependent. The relative amount of endothelin receptor A significantly decreased with age, whereas the
endothelin receptor B significantly increased with age. Compared to the other renal structures, a high endothelin
receptor density (endothelin receptor B » endothelin receptor A) was seen in the renal tubules and even more in
the glomeruli. Bosentan blocks both the pressor and depressor response of endothelin. Blocking of both endothelin
receptor subtypes using bosentan without application of endothelin, on the other hand, did not alter blood pressure,
heart rate, renal blood flow, water excretion or glomerular filtration rate, but significantly decreased sodium excre-
tion.
Introduction
Endothelins (endothelin-1, endothelin-2 and endothelin- and differ in their binding affinity to endothelin isopep-
3), a family of 21 amino acid peptides throught to regu- tides (endothelin receptor A: endothelin-1 ^ endothelin-
late local vasomotor tone, are the most potent vasocon- 2 » endothelin-3; endothelin receptor B: cndothclin-1
strictor substances yet identified. Endothelin-1 was the — endothelin-2 = cndothelin-3, endothelin receptor C:
first of the isopeptides to be characterized in the super- endothelin-3 » endothelin-2 = endothelin-1) as well as
natant of cultured vascular endothelial cells (1). The bio- in their expression by different cell types. In addition,
logical effects of endothelin are mediated by plasma- there are indications that there are also nuclear endo-
membrane-bound receptors. Three endothelin receptor thelin receptors (5). Apart from possessing vasoactive
subtypes (endothelin receptor A, B and recently C) have properties, endothelins have been shown to cause a wide
been cloned (2, 3, 4). Endothelin receptor C has not yet variety of biological activities in non-vascular tissues,
been described in mammals. The endothelin receptors including the kidney (6). The paracrine renal endothelin
belong to the family of rhodopsin-like receptors with system has been implicated in pathogenesis of many dis-
sevcn transmembrane domains coupled to a G-protein eases such as hypertension (7, 8) and impaired renal
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function in liver cirrhosis (9). Data from pharmacologi-
cal studies indicate that renal blood flow and tubular
function are partially controlled by both the endothelin
receptor A and endothelin receptor B (10). However,
little is known about the age-depedent expression, tissue
distribution and physiology of endothelin receptor sur>
types in the rat kidney. Therefore, the aim of our study
was to analyze the age-dependent expression of endo-
thelin receptor subtypes in the rat kidney using Scatch-
ard analysis, in vitro and in vivo receptor autoradiogra-
phy. Furthermore, we analyzed the effects of bosentan,
an orally active, mixed (A/B) endothelin receptor antag-
onist (11), on mean arterial blood pressure, glomerular
filtration rate, renal blood flow, heart rate and renal vas-
cular resistance in conscious chronically instrumented
rats. In addition, the effect of bosentan on water and
sodium excretion was analyzed as well.
Materials and Methods
Materials
Male Wistar rats (WKY) were obtained from Mallegard, Denmark
and fed a commercial diet (Altromin®, Altromin GmbH, Germany)
and were given water ad libitum. [125]Endothelin-l (74 EBq/mol
= 2000 Ci/mmol) was obtained from Du Pont (Germany) 32P-
dATP and 35S-UTP were from Amersham (Braunschweig, Ger-
many). Unlabeled endothelin-1 was from Peninsula Laboratories,
Inc. (Germany). The mixed (A/B) endothelin receptor antagonist
bosentan (Ro 47-0203, 4-/er/-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-
methoxy-phenoxy)-2,2'-bispyrimidine-4-yl]-benzenesulphonamide)
was a generous gift from Dr. Martine Clozel, Pharma Division, F.
Hoffmann-La Roche Ltd. (Basel, Switzerland). The selective endo-
thelin receptor ligands (BQ 123 and BQ 3020) were from Cali-
fornia Peptides Inc. (USA). Unless otherwise stated, all reagents
were of analytical grade and were purchased from Merck (Darm-
stadt, Germany) Boehringer-Mannheim (Mannheim, Germany) or
Sigma (Munich, Germany).
Membrane preparation
Membranes were prepared according to Nambi et al. (12). The rats
were sacrificed, and the cortex and medulla were carefully dis-
sected from each other. Approximately 150 mg of kidney medulla
or cortex were homogenized at 4°C in 10ml of 20 mmol/1
NaHC03 using a motor-driven pestle homogenizes The homoge-
nate was centrifuged at 4 °C for 15 min at 1000 g. The supernatant
was decanted and centrifuged at 4 °C for 30 min at 40000 g. The
pellet consisting of crude plasma membranes was resuspended in
assay buffer (1 g/1 bacitracin, 100 mmol/1 Tris-HCl, 5 mmol/1
MgCl2, and 1 g/1 bovine serum albumin, pH 7.4) at a protein con-
centration of 200 mg/1.
Binding assay for endothelin receptor A and B
Binding studies were performed as previously described with some
modifications (5). In order to analyze the expression of endothelin
receptor subtypes (endothelin receptor A, endothelin receptor B) in
the kidney, binding assays were performed in the presence or ab-
sence of the subtype-specific endothelin receptor ligands BQ 123
(3 μηιοΐ/ΐ) and/or BQ 3020 (14). The assay buffer for binding
studies contained 1 g/1 bacitracin, 100 mmol/1 Tris-HCl, 5 mmol/l
MgCl2, and 1 g/1 bovine serum albumin, pH 7.4. The total assay
volume was 150 μΐ. The [125I]endothelin-l tracer concentration was
kept constant at 40000 counts per minutes and tube, while the
concentration of unlabeled endothelin-1 was increased from 0 to
25 nmol/I (competition studies with "cold saturation"). Binding
studies were performed at room temperature for 120 min. Non-
specific binding was assessed in the presence of excess endothelin-
1 (5 μπΐοΐ/ΐ). After adding 1 ml of cold binding buffer, free and
receptor-bound radioactivity was separated by centrifugation at
30000g (4°C) for 15 min, and the pellets thus obtained were
washed two additional times with 1 ml of cold binding buffer. 125I
was counted in a Packard Gamma Counter (78% counting effi-
ciency for 125I).
Autoradiography of tissue endothelin receptor
subtypes
In vivo autoradiography
After anesthesia by intraperitoneal administration of pentobarbital,
the vena cava inferior was cannulated. In order to block the endo-
thelin receptor A, the endothelin receptor B or both receptor sub-
types BQ 123, BQ 3020 or BQ 123 and BQ 3020 (control) were
injected into the vena cava inferior followed by an injection of
[I25]endothelin-l in saline 15 min thereafter. The dosages of endo-
thelin-1, BQ 123 and BQ 3020 used did not alter the blood pressure
during the experiment (data not shown). Fifteen min later the rats
were sacrificed and the kidneys were perfused with 50 ml of ice-
cold saline, followed by fixation with 25 g/1 glutaraldehyde/50 g/1
formalin. Thereafter the kidneys were removed and embedded in
plastic material (Technovit®, Kulzer GmbH, Germany). The plastic
blocks were cut into 2.5^m-thick sections, layered with photo-
emulsion (K5 nuclear trace emulsion, Ilford, England) and stained
with hematoxylin and eosin. Evaluation was done by counting the
silver grains. The number of silver grains in a given area was di-
vided by the number of cell nuclei in the same area in order to
consider possible differences in density of cells.
Contact autoradiography of tissue endothelin receptor subtypes was
also performed. The kidneys were prepared as described above.
The sections were apposed on X-ray film and exposed for 20-30
days under intensifying conditions.
In vitro autoradiography
The frozen kidneys were cut into 5 μιη thick sections with a micro-
tome-cryostat. The sections were placed on precooled slides, air-
dried for 10 min and stored at —20 °C. Autoradiographic incuba-
tion was performed in the presence or absence of subtype specific
endothelin receptor ligands BQ 123 (3 μηιοΐ/i) and/or BQ 3020
(3 μπιοΐ/ΐ). The slides were covered with 100 μΐ binding buffer
(1 g/1 bacitracin, 100 mmol/1 Tris-HCl, 5 mmol/1 MgCl2, and 1 g/1
bovine serum albumin, pH 7.4) containing [125I]endothelin-l in a
concentration of 50 pmol/1 (4 MBq/1) and incubated in a moist
chamber for 2 h at room temperature. Radioactivity was withdrawn
by suction with a vacuum pump and the slides were washed 4
times for 10 min in 4 °C cold binding buffer. Finally the sections
were fixed for 20 min in 50 g/1 formalin, 25 g/1 glutaraldehyde,
9 g/1 NaCl. To remove the salts the slides were dipped briefly in
distilled water. Autoradiogramms with both endothelin receptor li-
gands (BQ 123, BQ 3020) served as a control. The sections were
layered with photoemulsion (K5 nuclear trace emulsion, Ilford,
England) and stained with hematoxylin and eosin. Evaluation was
done by counting the silver grains.
Contact autoradiography of tissue endothelin'receptor subtypes
The kidneys were prepared as described above. The sections were
mounted on X-ray film and exposed for 2 days under intensify-
ing conditions.
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Measurement of glomerular fi l tration rate, mean
arterial blood pressure, heart rate and renal blood
flow
Surgical procedures
One week prior to the acute experiments the rats were anaesthe-
tized with ether and the femoral artery and vein catheters were
implanted (3). Three'days before the start.of the experiments, flow-
probes (1KB with implantable connector, Transsonic Systems Inc.,
Ithaca, NY) were chronically implanted around the left renal artery.
Briefly, the left kidney was exposed by a retroperitoneal access.
The renal artery was carefully dissected using an operating micro-
scope to avoid damage to the renal nerves. The flowprobe was then
placed around the artery and, after the best signal had been
achieved, the probe was fixed in proper position using a small
envelope of Merocel Op-Wipe® (Merocel Corp., Mystic, Connecti-
cut, USA) covering the probe and the artery at the point of reflector
attachment. To improve signal conductance, the envelope was
filled with ultrasound gel. All catheters and cables were led subcu-
taneously to the rat's neck.
Circulatory measurements
Mean arterial blood pressure and heart rate were measured via
the arterial line with a Statham pressure transducer P23Db and
a Gould pressure processor coupled to a Gould Brush 2600
recorder. Renal blood flow was measured via the chronically
implanted flowprobe with a transit time flowmeter (T106, Tran-
sonic System Inc., Ithaca, NY, USA) and continuously recorded
on a Gould Brush 2600 recorder. The Transonic flowmeter sys-
tem determines absolute volume flow by measuring the differ-
ence (picosecond range) between the upstream and downstream
time of flight of a wide beam of ultrasound across the blood
vessel (14). The flowprobes were precalibrated by the producer
and measured absolute blood flow with an accuracy of ± 2%.
Renal vascular resistance was calculated as mean arterial blood
pressure divided by renal blood flow.
Measurement of glomerular filtration rate
Glomerular filtration rate was measured using the inulin single-
shot method (15). The single-shot clearance was evaluated by dis-
playing a two-compartment model with resolution of the plasma
inulin concentrations into two rnonoexponential functions. The rats
received an intravenous i.v. bolus injection of 150 mg of inulin
(Inutest®). Blood samples for determination of serum mulin con-
centrations were drawn at 0, 15, 30, 90, 135 and 180 minutes after
injection. Inulin was measured by a modified -fructosidase
method (16). Glomerular filtration rate is expressed as ml/min per
100 g body weight.
Effects of bosentan on the haemodynamic responses to
endothel in
We tested the effects of increasing doses of the endothelin antago-
nist (bosentan or Ro 47-0203) on the haemodynamic responses to
200 ng endothelin (i. v.) in 16-week-old Wistar Kyoto rats. The rats
received i.v. bolus injections of 200 ng endothelin 5 minutes after
i.v. injections of vehicle. After baseline values had again been
reached, the rats received increasing doses (0.3, 3, 10, 30, and 100
mg/kg) of bosentan, five minutes prior i.v. bolus injections of 200
ng endothelin, respectively. Bosentan was dissolved in water at a
concentration of 15 g/1. The highest volume needed for this
study was 2ml and did not alter blood pressure, heart rate or
renal blood flow itself as shown by i. v. administration of vehi-
cle. The animals were allowed to attain baseline values of all
parameters measured between injections of endothelin with the
respective endothelin antagonist. The conscious chronically in-
strumented rats received 200 ng of endothelin-1 and the doses
(0.3, 3, 10, 30, and 100 mg/kg, respectively) of bosentan with
breaks of 12 hours between the single experiments due to the
well known tachyphylaxis after repeated injections of endothelin.
Using this protocol we found no evidence for tachyphylaxis after
repeated injections of endothelin with respect of blood pressure,
renal blood flow and heart rate.
Effects of bosentan on glomerular f i l t ra t ion rate,
mean arterial blood pressure, heart rate and renal
blood flow
To examine the effects of bosentan on resting mean arterial blood
pressure, heart rate, renal blood flow and renal vascular resistance
in 16-week-old Wistar Kyoto rats, the rats received cumulative i. v.
bolus injections of the mixed (A/B) endothelin receptor antagonist
bosentan (3 mg/kg) every 15 minutes until a total load of 30 mg/
kg was obtained.
The experimental protocol for the determination of glomerular
filtration rate was performed on two consecutive days. On day one
16-week-old male Wistar Kyoto rats received either an i.v. bolus
injection of bosentan (100 mg/kg) or an i.v. bolus injection of
vehicle (0.3 ml 9 g/1 NaCl), followed by an i. v. bolus injection of
150 mg inulin 5 minutes later. At 0, 15, 30, 90, 135 and 180 min-
utes after injection of inulin, blood samples (200 μΐ) were taken
from the arterial catheter for determination of serum inulin concen-
trations. On day two the animals underwent the same protocol but
received bosentan instead of vehicle and vica versa.
Tab. 1 Receptor density and binding constants of endothelin re-
ceptor A and endothelin receptor Β derived from [125I]endo-
thelin-1 binding in the presence of the subtype-specific ligands to
kidney membranes of 4- and 16-week-old Wistar Kyoto rats.
Wistar Kyoto rats, 4 weeks old Wistar Kyoto rats, 16 weeks old
Cortex
Cortex
Medulla
Medulla
Endothelin receptor A
Endothelin receptor Β
Endothelin receptor A
Endothelin receptor Β
Bmax
(frnol/mg)
308 ± 25
186 ±29
341 ± 31
471 ± 65
Kd
(nmol/1)
0.62 ± 0.06
1.2 ±0.1
0.97 ± 0.09
1.3 ±0.11
"max
(fmol/mg)
174 ± 19*
363 ± 42*
130 ± 34*
780 ± 59*
K<,
(nmol/1)
0.59 ± 0.02
0.9 ±0.04
1.2 ±0.09
2.3 ±0.6**
Data from Scatchard plots of [125I]endothelin-l binding studies.
To analyse expression of receptor subtypes, binding assays were
performed in the presence of the subtype-specific ligands (BQ 123
or BQ 3020). Non-specific binding was assessed in the presence
of 5 μιυοί/ΐ of unlabeled endothelin-1. It ranges between 5-10%.
For details see Material and Methods. Values are means ± SD of
6 separate animals in each group. (*p < 0.05 compared to the cor-
responding Bmax in 4-week-old Wistar Kyoto rats, ##p < 0.05
compared to the corresponding K^ in 4-week-old Wistar Kyoto rats.
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Effects of bosentan on sodium and water excretion
The rats were divided into three groups.
Group 1: 8 control rats without bosentan treatment. The rats re-
ceived vehicle (1.5 ml suspension of 50 g/1 arabic gum) by gastric
gavage at the hours 0, 8, 16 for two days.
Group II: 8 rats with bosentan treatment (30 mg/kg · d). ·
Group III: 8 rats with bosentan treatment (100 mg/kg - d).
Bosentan (micronized free sulphonamide) was used in suspension
in 50 g/1 arabic gum (vehicle), prepared freshly and administered
by gastric gavage with a polyethylene stomach tube (10 or 33.3
mg/kg body weight in 1.5 ml vehicle, respectively) by gastric ga-
vage at the hours 0, 8, 16 for two days. Urine was collected for
the determination of sodium, potassium and volume.
Results
Endothel in receptor binding experiments
Scatchard analysis revealed only one type of endothelin
receptor A and B binding sites (data not shown). The
endothelin receptor A and B binding constants (IQ) in
the renal cortex were similar for 4- and 16-week-old
Wistar Kyoto rats. On the other hand, the endothelin
receptor B binding constants (K^) in the renal medulla
increased in an age-dependent manner (tab. 1).
The endothelin receptor A density (Bmax) in the whole
kidney decreased with age, whereas the endothelin re-
ceptor B density (Bmax) increased with age (p < 0.05 in
all cases, tab. 1). The endothelin receptor B/endothelin
receptor A ratio in the renal cortex is 0.60 in 4-week-
old Wistar Kyoto rats and increased to 2.09 in 16-week-
old Wistar Kyoto rats. The endothelin receptor B/endo-
thelin receptor A ratio in the renal medulla is 1.38 in 4-
week-old Wistar Kyoto rats and increased to 6.00 in 16-
week-old Wistar Kyoto rats. These data are calculated
from table 1.
± 0.6 fold increased in the glomeruli of 4-week-old
Wistar Kyoto rats (n = 6, ρ < 0.05) compared to the
density of endothelin receptor Β (data not shown). Data
concerning the expression of glomerular endothelin re-
ceptor subtypes obtained by in vivo or in vitro auto-
la
Ib
lc
Receptor autoradiography
Non-specific binding was very low after blocking the
endothelin receptors with BQ 123 and BQ 3020, as
shown in figures 1-4. Receptor autoradiography
showed that both subtypes (endothelin receptor A and
endothelin receptor B) were present throughout the
whole kidneys. Using in vivo autoradiography, the ma-
jority of binding sites in the kidney was observed in the
cortex, mainly within the glomeruli. Both the endothelin
receptor A and the endothelin receptor Β were homoge-
neously distributed throughout the glomeruli (fig. 3). By
counting the silver grains, we observed a 4.6 ± 0.4 fold
increased density of endothelin receptor B in the glo-
meruli (n = 6, ρ < 0.01) compared to the density of en-
dothelin receptor A in 16-week-old Wistar Kyoto rats,
whereas the density of endothelin receptor A is 1.9
Fig. 1 Macroscopic in vitro autoradiography of endothelin recep-
tor A and endothelin receptor Β protein expression in the kidney
of a 16-week-old Wistar Kyoto rat;
a) endothelin receptor A expression;
b) endothelin receptor Β expression;
c) non-specific binding after blocking the endothelin receptor A
and endothelin receptor B with BQ 123 and BQ 3020.
Magnification: 3X.
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radiography were equal. Contrary to the in vivo auto-
radiography, in vitro autoradiography revealed in high
density of endothelin receptor B in medullary collecting
ducts (figs. 1, 2) in 4 and moreover 16-week-old Wistar
Kyoto rats. This was not an effect of length of tissue
exposure to film, because in vivo and in vitro studies
with a longer or shorter exposure time revealed the
same differences.
2a
2b
2c
"yf~··W .· .·.'·< ·. ··*
fe>i-:.o:' -.^
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Fig. 2 Macroscopic in vivo autoradiography of endothelin recep-
tor A and endothelin receptor B protein expression in the kidney
of a 16-week-old Wistar Kyoto rat;
a) endothelin receptor A expression;
b) endothelin receptor B expression;
c) non-specific binding after blocking the endothelin receptor A
and endothelin receptor B with BQ 123 and BQ 3020.
Magnification: 3X.
Effects of bosentan on the haemodynamic
responses to endo the l in
Intravenous bolus injections of 200 ng endothelin pro-
duced a biphasic blood pressor response: an initial short-
lasting depressor effect was followed by a long-lasting
blood pressure elevation. The changes in blood pressure
were accompanied by reciprocal alterations in heart rate.
In contrast, renal blood flow exhibited a monophasic
response pattern (long-lasting decrease of renal blood
flow) after endothelin i. v. Increasing doses of the endo-
thelin antagonist induced a dose dependent blockade of
the depressor effects to 200 ng endothelin i. v., maximal
blockade was achieved after 10 mg/kg. Qualitatively the
same was observed for the heart rate response during
the depressor phase. In contrast, the pressor effect to
endothelin i. v. was initially potentiated after increasing
doses of the antagonist, with a maximum of potentiation
after 3 mg/kg. After the highest dose of the endothelin
antagonist used in this study (100 mg/kg) the pressor
effect was blocked by 89.7%, whereas the heart rate re-
sponse was blocked by 67.5%. The effects of the endo-
thelin antagonist on the changes in renal blood flow to
endothelin i. v. were qualitatively and quantitatively sim-
ilar to the effects on the pressor response, with a maxi-
mum of potentiation after 3 mg/kg and a maximal inhi-
bition after 100 mg/kg of 92.5%.
Effects of bosentan on renal blood flow,
glomerular f i l t ra t ion rate, renal vessel
resistance, heart rate and mean arterial blood
pressure
Cumulative i. v. bolus doses (3 mg/kg every 15 min) of
the mixed (A/B) endothelin receptor antagonist did not
alter renal blood flow, renal vessel resistance, heart rate
or mean arterial blood pressure in 16-week-old Wistar
Kyoto rats (fig. 8).
A bolus injection of the endothelin antagonist induced
no alterations of glomerular filtration rate in 16-week-
old Wistar Kyoto rats (1.21 ± 0.27 versus 1.19 ±0.15
ml/min per 100 g body weight). The bolus injection of
bosentan caused a minor, non-significant reduction of
mean arterial blood pressure by 3.6 ± 1.08 mmHg in
Wistar Kyoto rats.
Effects of bosentan on water and
sodium excretion
The mixed (A/B) endothelin receptor antagonist bosen-
tan (100 mg/kg-d p.o.) significantly (p < 0.05) de-
creased sodium excretion in 16-week-old male Wistar
Kyoto rats, whereas water excretion was not altered
Eur J Clin Chem Clin Biochem 1995; 33 (No 8)
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by bosentan (fig. 5). The effects after giving a lower with the higher dosage (100 mg/kg · d), indicating that
dosage of bosentan (30 mg/kg · d) on water and so- the lower dosage of bosentan also significantly
dium excretion were not different (as analyzed by (p < 0.05) decreased sodium excretion, whereas water
impaired t-test, data not shown) from those obtained excretion was not altered.
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Fig. 3 Microscopic in vivo autoradiography of endothelin recep-
tor A and B protein expression in the glomeruli of a 16-week-old
Wistar Kyoto rat;
a) endothelin receptor A expression;
b) endothelin receptor B expression;
c) non-specific binding after blocking the endothelin receptor A
and endothelin receptor B with BQ 123 and BQ 3020.
Magnification: 555X.
Fig. 4 Microscopic in vivo autoradiography of endothelin recep-
tor A and B protein expression in the renal tubuli of a 16-week-
old Wistar Kyoto rat;
a) endothelin receptor A expression;
b) endothelin receptor B expression;
c) non-specific binding after blocking the endothelin receptor A
and endothelin receptor B with BQ 123 and BQ 3020.
Magnification: 555X.
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Fig. 5 The mixed (A/B) endothelin receptor antagonist bosentan
decreased sodium excretion in 16-week-old Wistar Kyoto rats,
whereas water excretion was not altered by bosentan. Bosentan
(100 mg/kg · d) or vehicle was given by gastric gavage (n = 8;
means ± SEM).
Discussion
Age-dependent differences in renal endothelin
receptor expression
Binding studies showed that the endothelin receptor B/
endothelin receptor A ratio in the kidney of Wistar Ky-
oto rats is age-dependent, suggesting age-dependent dif-
ferences in the renal physiology of the paracrine endo-
thelin system. Since it is well known that endothelin
knock out mice have craniofacial abnormalities (17), our
data might indicate (but does not prove) that age-depen-
dent expression of endothelin receptor subtypes play a
major role in the pre- and postnatal development of the
rat kidney.
In addition, the endothelin receptor B binding constant
in the renal medulla of Wistar Kyoto rats is also age-
dependent. We suggest that structural alterations of en-
dothelin receptor B (phosphorylation or glycosylation)
may occur with age. N-glycosylation sites were iden-
tified in the outer cell domain of both endothelin recep-
tor subtypes (29 3).
Receptor autoradiography
The highest endothelin receptor density in the rat kidney
was seen in the glomeruli using in vivo or in vitro auto-
radiography (fig. 3), whereas in the human kidney the
highest endothelin receptor density was present within
the renal blood vessels and medullary tubules as shown
by Karet et al. (29) using in vitro receptor autoradiogra-
phy. In comparison to the rat kidney (fig. 3) the glomer-
uli in the human kidney had a markedly lower density
of endothelin receptors (29). However, the endothelin
receptor B/endothelin receptor A ratio in the kidney is
similar in rats (tab. 1) and humans (29) as seen by
Scatchard analysis.
The endothelin receptor B within the rat glomeruli
seems to be located on the glomerular endothelial cells,
as suggested by data from Fumy a et al. (18). Using
electron microscopic autoradiography, they found that
the endothelin-1 binding sites in the kidney were prefer-
ably localized on the fenestrated endothelial cells of glo-
meruli and peritubular capillary endothelial cells. The
glomerular endothelin receptor A is most probably ex-
pressed by mesangial cells (19, 20).
On the other hand, our study clearly demonstrated dif-
ferent patterns of endothelin receptor subtype distribu-
tion in rat renal medulla depending on the method used
(in vivo or in vitro autoradiography, figs. 1 and 2). Ana-
lyzing the total renal [125I]endothelin-l binding this phe-
nomena was also seen by Koseki et al. (31). The reason
for this discrepancy in our study and in the above men-
tioned study (31) between in vitro and in vivo receptor
autoradiography is unknown, but there are two feasible
explanations:
i) even very low concentrations of endothelin receptor-
ligands may alter the renal microcirculation in vivo re-
sulting in alterations of radioligand distribution or
ii) [125]endothelin-l access to the tissues is not the same
in vitro or in vivo due to the hydrophobic nature of the
receptor ligands.
In any case in vivo receptor autoradiography seems to
be a suitable method for preferential labeling of vascular
endothelin receptors, whereas in vitro autoradiography
labels both vascular and non-vascular endothelin recep-
tors.
Effects of bosentan on the haemodynamic
responses to endothelin
The mixed endothelin receptor antagonist bosentan was
chosen for physiological studies, because this antagonist
is orally active thus being of clinical relevance, whereas
most of the selective yet described endothelin receptor
A and B antagonists are not orally active. Due to the
short supply of bosentan, our analysis was limited to 16-
week-old Wistar Kyoto rats. Bosentan is able to block
in vivo both the pressor and depressor response to endo-
thelin as shown in figure 6 and by others (11, 28), indi-
cating that bosentan is an endothelin receptor A and B
antagonist. However, in contrast to Gardiner et al. (28),
our study revealed no effect of bosentan at a dosage of
30 mg/kg i. v. on the pressure response to 200 ng endo-
thelin-1 i.v. In our hands the endothelin-1 induced pres-
sure effect was completely blocked only after 100 nig/
Eur J Clin Chem dim Biochem 1995; 33 (No 8)
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Fig. 6 Effects of increasing doses (0, 0.3, 3, 10, 30 and 100 mg/
kg) of bosentan op the maximum changes in mean arterial blood
pressure and heart rate during the depressor phase (left panel) and
the pressor phase (right panel) after 200 ng endothelin i. v. in 16-
week-old Wistar Kyoto rats. Data are represented as means
+ SEM.
kg bosentan (fig. 6), whereas the study of Gardiner et
al. demonstrated a partial blockade of the endothelin-1
induced pressure effect after 30 mg/kg bosentan i.v.
They suggested, but did not prove by a dose-dependent
study, that the dose of bosentan used in their study (30
mg/kg) was insufficient to fully inhibit the haemody-
namic effects of endothelin-1. In the present study we
were able to demonstrate that the endothelin-1 induced
pressure response was completely blocked after 100 mg/
kg bosentan i. v. (fig. 6). These minor differences con-
cerning the bosentan dosage needed for complete block-
age of the pressure response to endothelin-1 may be due
to the different rat strains used in our study (Wistar Ky-
oto rats) and the study of Gardiner et al. (Long Evans
rats).
The depressor response to endothelin is mediated by the
endothelin receptor B-induced nitric oxide synthesis
(21). Based on pharmacological studies using selective
endothelin receptor A or B ligands, it was shown that
the pressor response to endothelin-1 in rats is mediated
by both the endothelin receptor A and B. Warner et al.
(22) suggested the terms endothelin receptor Bl to de-
scribe the endothelin receptor B that mediates endothe-
lium-dependent nitric oxide-induced vasorelaxation and
endothelin receptor B2 to describe the endothelin recep.
tor B that mediates vasoconstriction. However, several
points should be addressed in this context:
tentiated after increasing doses of bosentan. This obser-
vation may also reflect the above-mentioned higher local
concentrations of bosentan in the endothelin cell layer
than in the smooth muscle cells of blood vessels contrib-
uting to blood pressure, since the inhibitory effect of
bosentan on the pressor effect is reduced by the concom-
itant inhibitors of the depressor effect. Only after having
blocked all the endothelin receptor B (endothelin recep-
tor Bl), the net effect of bosentan resulted in lowering
the mean arterial blood pressure.
iii) In contrast to systemic blood pressure and heart rate,
renal blood flow exhibited a monophasic response
pattern to endothelin (long-lasting decrease of renal
blood flow without an initial increase of renal blood
flow; fig. 7), suggesting that the endothelin receptor Bl
mediated vasorelaxation is of minor importance or miss-
ing in the rat renal vascular beds.
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Fig. 7 Effects of increasing doses (0, 0.3, 3, 10, 30 and 100 mg/
kg) of bosentan on the maximum changes in renal blood flow and
renal vascular resistance after 200 ng endothelin i.v. in 16-week-
old Wistar Kyoto rats. In contrast to the effects of bosentan on the
maximum changes in blood pressure and heart rate, renal blood
flow exhibited monophasic response pattern. Data are represented
as mea'ns + SEM.
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Effects of bosentan on mean arterial blood
pressure, heart rate, renal blood flow,
glomerular filtration rate, water and sodium
excretion in 16-week-old Wistar Kyoto rats
In contrast to deoxycorticosterone acetate-salt hyperten-
sive rats (23) or spontaneously hypertensive rats (24),
bosentan does not alter mean arterial blood pressure,
heart rate, renal blood flow or glomerular filtration rate
in 16-week-old Wistar Kyoto rats (fig. 8), indicating that
these parameters are not mainly controlled by the para-
crine endothelin system in normotensive rats. It is also
possible that the net effect of blocking both the endo-
thelin receptor A and B resulted in no alterations of the
above mentioned quantities. Therefore, subtype specific
antagonists are necessary to answer this question. So-
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Fig. 8 Effects of cumulative i. v. bolus doses (3 mg/kg) of the
endothelin antagonist bosentan on mean arterial blood pressure,
heart rate, renal blood flow and renal vascular resistance in 16-
week-old male Wistar Kyoto rats. Arrows indicate time of injection
(injection intervals: 15 minutes). Data are presented as means
± SEM, n = 8).
dium excretion, on the other hand, is significantly re-
duced by the endothelin receptor antagonist bosentan,
indicating that the tubular sodium transport in the renal
medulla is under the control of the renal endothelin sys-
tem. Our data are in agreement with studies showing an
increased urinary sodium excretion caused by intrave-
nous administration of endothelin receptor agonists (en-
dothelin-1) (25). Some of these natriuretic effects of en-
dothelin may be due to inhibition of sodium reabsorption
in the renal collecting duct by action on both apical so-
dium entry and basolateral Na+/K+-ATPase (26, 27). In-
travenous administration of endothelin-1 or endothelin-
3 also reduces water reabsorption in the rat kidney (25).
However, we did not see any effect on water excretion
after blocking both the endothelin receptor A and B with
bosentan, suggesting that the renal paracrine endothelin
system in normotensive rats without exogenous stimula-
tion plays a minor role in the regulation of water excre-
tion, but is involved in the regulation of sodium excre-
tion. The observed effects after intravenous endothelin
administration on renal function (25, 26, 27) most prob-
ably reflect the situation in an activated paracrine system
and therefore are different from the situation without
exogenous stimulation.
With respect to heart rate and blood pressure our data
are in agreement with a recent report by Teerlink et al.
(30). They also observed no significant changes in mean
arterial blood pressure and heart rate in anesthetized
open-chest dogs after blocking the endogenous endo-
thelin system using bosentan.
In summary, this study showed that the renal endothelin
receptor A and B expression is age-dependent. The rela-
tive amount of endothelin receptor A decreases signifi-
cantly with age. The endothelin receptor B is the pre-
dominant endothelin receptor of the adult rat kidney.
Compared to the other renal structures, a high endo-
thelin receptor density (endothelin receptor A and B)
was seen in the renal tubules and even more in the glo-
meruli. The mixed (A/B) endothelin receptor antagonist
bosentan blocks both the pressor and depressor response
of endothelin. Blocking of both endothelin receptor sub-
types using bosentan without application of endothelin,
on the other hand, did not alter blood pressure, heart
rate, renal blood flow, water excretion and glomerular
filtration rate, but significantly decreased sodium excre-
tion.
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